COVER -- HALF-TITLE -- TITLE -- COPYRIGHT -- CONTENTS -- CONTRIBUTORS -- EDITORS' PREFACE -- The viruses in our past, the viruses in our future -- THE PREMISE -- HISTORY OF THE CONTINENTS -- HISTORIC CHANGES IN HUMAN ECOLOGY AND PATTERNS OF INFECTION -- THE YELLOW FEVER EXAMPLE -- SOME LESSONS FROM TODAY -- Hantavirus pulmonary syndrome (HPS) -- Ebola virus -- Rift Valley fever (RVF) -- Nipah -- WHAT SHOULD WE EXPECT IN THE FUTURE? -- WHAT CAN THE SCIENTIFIC COMMUNITY DO? -- Research -- Public health -- Vaccines -- IN CONCLUSION -- ACKNOWLEDGEMENTS -- REFERENCES -- Dynamics and epidemiological impact of microparasites -- INTRODUCTION -- POPULATION DYNAMICS OF CHILDHOOD INFECTIONS - OBSERVED PATTERNS -- The data -- THE SEIR MODEL FOR CHILDHOOD DISEASE DYNAMICS -- MODELLING OBSERVED EPIDEMIC PATTERNS AND DYNAMICAL TRANSITIONS -- Recurrent epidemics -- Impact of birth rate variations and vaccination -- Stochasticity, space and synchrony -- COMPARATIVE IMPACT AND DYNAMICS OF MICROPARASITES -- CONCLUSION -- ACKNOWLEDGEMENTS -- REFERENCES -- The continuing threat of bunyaviruses and hantaviruses -- INTRODUCTION -- GENOME CODING AND REPLICATION STRATEGIES -- EVOLUTIONARY POTENTIAL OF BUNYAVIRUSES AND HANTAVIRUSES -- BIOLOGY OF BUNYAVIRUSES AND HANTAVIRUSES -- BUNYAVIRUS AND HANTAVIRUS DISEASE -- BUNYAVIRUS NON-STRUCTURAL PROTEINS -- CONCLUSION -- ACKNOWLEDGEMENTS -- REFERENCES -- Calicivirus, myxoma virus and the wild rabbit in Australia: a tale of three invasions -- INTRODUCTION -- THE RABBIT -- Invasion -- Evolution of the invader -- Lessons -- THE MYXOMA VIRUS -- Invasion -- Evolution of the invader -- Lessons -- CALICIVIRUS -- Invasion -- Evolution of virus and host -- Lessons -- SIMILARITIES AND DIFFERENCES IN THE THREE INVASIONS -- REFERENCES -- Potential of influenza A viruses to cause pandemics -- INTRODUCTION -- INFLUENZA VIRUSES.

HOST RANGE RESTRICTION -- PATHOGENICITY -- AVIAN-TO-MAMMALIAN TRANSMISSION -- SURVEILLANCE -- REFERENCES -- The hepatitis viruses as emerging agents of infectious diseases -- INTRODUCTION -- THE FIVE VIRAL AGENTS OF HEPATITIS -- THE DISEASE BURDEN ASSOCIATED WITH HEPATITIS VIRUS INFECTION -- THE HEPATITIS VIRUSES AS EMERGING AGENTS OF INFECTION -- HEPATITIS A VIRUS -- Virology -- The changing threat of hepatitis A -- HEPATITIS E VIRUS -- HEPATITIS B VIRUS -- Molecular virology -- Natural history and the host immune response -- The emerging issue of natural and drug-selected HBV mutants -- HEPATITIS D VIRUS -- HEPATITIS C VIRUS -- Molecular virology -- Natural history and disease pathogenesis -- Hepatitis C as an emerging infection -- Prospects for an HCV vaccine -- CONCLUSION -- REFERENCES -- The emergence of human immunodeficiency viruses and AIDS -- INTRODUCTION -- THE VIRUSES -- ORIGINS AND DIVERSITY -- EPIDEMIOLOGY -- HIV PATHOGENESIS -- Disease parameters -- HIV dynamics and progression -- Cellular tropism and disease -- CONTROLLING HIV INFECTION -- Anti-retroviral therapy -- HIV vaccine development -- Public health control and prevention -- CONCLUSIONS AND PROSPECTS -- ACKNOWLEDGEMENTS -- REFERENCES -- Morbilliviruses: dangers old and new -- INTRODUCTION -- HISTORY -- CONTROL -- HIDDEN VIRUS -- HOST RANGE -- NEW MORBILLIVIRUSES -- EVOLUTION -- CONSEQUENCES -- CONCLUSIONS -- REFERENCES -- Structure-function analysis of prion protein -- INTRODUCTION -- VECTORS FOR THE EXPRESSION OF PrP IN THE CNS -- SUSCEPTIBILITY TO SCRAPIE OF PrP KNOCKOUT MICE EXPRESSING AMINO-PROXIMALLY TRUNCATED PrP -- ATAXIC SYNDROME IN PrP KNOCKOUT MICE EXPRESSING PrP TRUNCATED TO POSITIONS 121 OR 134 -- DELETIONS IN THE Prnp LOCUS LEADING TO ATAXIA -- CONCLUDING REMARKS -- REFERENCES -- Endogenous retroviruses and xenotransplantation -- THE PROMISE OF XENOTRANSPLANTATION.

SOURCE ANIMALS FOR XENOTRANSPLANTATION -- CHALLENGES FOR XENOTRANSPLANTATION -- INTRODUCTION TO ENDOGENOUS RETROVIRUSES -- ENDOGENOUS RETROVIRUSES AS A THREAT IN XENOTRANSPLANTATION -- PROPERTIES OF PERVs -- GENETIC DISTRIBUTION OF PERVs -- EXPRESSION OF PERVs -- IN VIVO REPLICATION OF PERVs -- PATHOGENICITY OF ENDOGENOUS RETROVIRUSES -- RISK ASSESSMENT -- REFERENCES -- Gammaherpesviral infections and neoplasia in immunocompromised populations -- INTRODUCTION -- GAMMAHERPESVIRUSES -- EPSTEIN-BARR VIRUS -- Diseases in the immunocompetent host -- Diseases in the immunosuppressed host -- KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS -- KSHV latent proteins -- KSHV and immunity -- REFERENCES -- Structure and function of the proteins of Marburg and Ebola viruses -- INTRODUCTION -- PATHOPHYSIOLOGY OF FILOVIRUS INFECTIONS -- GENOME AND GENOME PRODUCTS OF FILOVIRUSES -- PROTEOLYTIC PROCESSING OF THE FILOVIRUS GLYCOPROTEIN AS A POTENTIAL DETERMINANT OF PATHOGENICITY -- POTENTIAL FILOVIRUS MECHANISMS INTERFERING WITH HOST DEFENCE -- REFERENCES -- Epidemic dengue/dengue haemorrhagic fever as a public health problem in the 21st century -- INTRODUCTION -- NATURAL HISTORY -- CLINICAL PRESENTATION -- CHANGING EPIDEMIOLOGY OF DENGUE -- FACTORS RESPONSIBLE FOR THE GLOBAL RESURGENCE OF DENGUE -- DISEASE PREVENTION AND PROSPECTS FOR THE FUTURE -- REFERENCES -- Borna disease virus - a threat for human mental health? -- PROLOGUE -- THE AGENT -- Biological properties -- Molecular and biochemical properties -- Replication, transcription, translation and immunogenicity -- The virion -- THE INFECTION -- Virus spread in the body -- Spread in nature -- Human infections and disease -- Monitoring -- Seroprevalence -- Antigens -- Immune complexes -- Nucleic acid -- Human isolates -- Antiviral treatment -- RELEVANCE OF ANIMAL MODELS -- Rabbit -- Rat -- Mouse -- Cat -- Birds.

Primate-like animals -- EPILOGUE -- DEDICATION -- ACKNOWLEDGEMENTS -- REFERENCES -- Antiviral drug development and the impact of drug resistance -- INTRODUCTION -- THE DRUG DEVELOPMENT PROCESS -- SELECTING THE DISEASE -- DEFINING THE DESIRED PRODUCT -- SELECTING THE MOLECULAR TARGET -- Viral or cellular? -- Selecting a viral target -- IDENTIFICATION OF A LEAD MOLECULE -- Screening against a molecular target -- Rational drug design -- Screening against virus replication -- DEVELOPMENT OF THE CLINICAL CANDIDATE -- Resistance studies with the clinical candidate -- EARLY STUDIES IN MAN -- Studies in healthy volunteers -- Early studies in infected individuals -- FULL CLINICAL DEVELOPMENT -- CONCLUSIONS -- REFERENCES -- INDEX.